T2D experts weigh in
on TRAJENTA® & JENTADUETO®.
With CARMELINA®, the simplicity of TRAJENTA® is reinforced by the reinforced safety profile, established efficacy and the convenience of one dose once daily
Simplicity of Trajenta® within the DPP4i class: established efficacy, established safety profile and convenience of one dose once daily
TRAJENTA®: Proven efficacy.
Trajenta® constently lowers HbA1c in line with other DPP4i
Trajenta®'s efficacy is fully on par with other DPP4 inhibitors
TRAJENTA®: Safety profile - Cardiovascular outcome trial program.
CAROLINA® is the only CVOT within DPP4i class to assess the cardiovascular safety of linagliptin versus an active comparator
CARMELINA® is unique as it includes patients with high cardiovascular risk and, in many instances with impaired renal function
TRAJENTA®: Safety profile - CARMELINA® Results.
With CARMELINA®, linagliptin demonstrated a long-term cardiovascular safety profile in patients with T2D and showed no increase in risk of hospitalisation for heart failure
CARMELINA® is the only study that included a kidney-related secondary end point. The study showed no difference in outcome between TRAJENTA® and placebo
Trajenta® can be used in a broad range of T2D patients, independent of kidney function, whenever a DPP4i is needed
JENTADUETO®: Powerful HbA1c reductions for high baseline
Prof. Per-Henrik Groop
SPC metformin with linagliptin: the only DPP4i that does not require dose reduction when renal function declines
Prof. Stefano Del Prato
Linagliptin has demonstrated high efficacy in newly diagnosed patients with high baseline HbA1c
55-year-old male; HbA1c 8%; on metformin; normal kidney function; Trajenta® is an appropriate option when a DPP4i is needed
78 year old woman, low GFR, on metformin, HbA1c of 8%. Adding Linagliptin as SPC was appropriate. After GFR further declined linagliptin daily dose was maintained and metformin was switched to insulin